The FDA announced on Oct. 13, 2026, that Par Health USA, LLC voluntarily recalled Argatroban Injection USP due to particulate matter hazards. The recall affects 18,991 vials distributed nationwide.
How to tell if you have it
- Brand: Par Health USA
- Product: Argatroban Injection USP
- Strength/Size: 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial
- NDC: 42023-182-01
- Lot Codes: 83449, 82682, 86714, 87302, 87560, 87753, 88401, 88614, 88836, 90220, 91216, 91219, 92004, 92006, 92009, 92596, 92782, 93107, 93329, 93890
- Expiration Dates: 10/2026, 11/2026, 02/2027, 03/2027, 04/2027, 05/2027, 06/2027, 07/2027, 08/2027, 09/2027
- Quantity: 18,991 vials
The hazard
The product contains particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the solution. The FDA classified this as a Class I recall.
Context
GovInfoNow's records show Par Health USA, LLC has two other recalls on record since June 12, 2026. On Sept. 8, 2026, the company recalled Buprenorphine Injections due to crystallization. Other recent recalls of similar products include American Regent Epinephrine Injection Recall (Aug. 11, 2026), American Regent Papaverine HCl Injection Recall (July 24, 2026), and American Regent Tralement injection recall (July 24, 2026).